BACKGROUND: Gout is a common type of inflammatory arthritis in patients seen by primary care physicians. PURPOSE: To review evidence about treatment of acute gout attacks, management of hyperuricemia to prevent attacks, and discontinuation of medications for chronic gout in adults. DATA SOURCES: Multiple electronic databases from January 2010 to March 2016, reference mining, and pharmaceutical manufacturers. STUDY SELECTION: Studies of drugs approved by the U.S. Food and Drug Administration and commonly prescribed by primary care physicians, randomized trials for effectiveness, and trials and observational studies for adverse events. DATA EXTRACTION: Data extraction was performed by one reviewer and checked by a second reviewer. Study quality was assessed by 2 independent reviewers. Strength-of-evidence assessment was done by group discussion. DATA SYNTHESIS: High-strength evidence from 28 trials (only 3 of which were placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout. Moderate-strength evidence suggests that low-dose colchicine is as effective as high-dose colchicine and causes fewer gastrointestinal adverse events. Moderate-strength evidence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attacks after 1 year or more. High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting urate-lowering therapy, and moderate-strength evidence indicates that duration of prophylaxis should be longer than 8 weeks. Although lower urate levels reduce risk for recurrent acute attacks, treatment to a specific target level has not been tested. LIMITATION: Few studies of acute gout treatments, no placebo-controlled trials of management of hyperuricemia lasting longer than 6 months, and few studies in primary care populations. CONCLUSION: Colchicine, NSAIDs, and corticosteroids relieve pain in adults with acute gout. Urate-lowering therapy decreases serum urate levels and reduces risk for acute gout attacks. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality. (Protocol registration: http://effectivehealth-care.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf).
BACKGROUND: Gout is a common type of inflammatory arthritis in patients seen by primary care physicians. PURPOSE: To review evidence about treatment of acute gout attacks, management of hyperuricemia to prevent attacks, and discontinuation of medications for chronic gout in adults. DATA SOURCES: Multiple electronic databases from January 2010 to March 2016, reference mining, and pharmaceutical manufacturers. STUDY SELECTION: Studies of drugs approved by the U.S. Food and Drug Administration and commonly prescribed by primary care physicians, randomized trials for effectiveness, and trials and observational studies for adverse events. DATA EXTRACTION: Data extraction was performed by one reviewer and checked by a second reviewer. Study quality was assessed by 2 independent reviewers. Strength-of-evidence assessment was done by group discussion. DATA SYNTHESIS: High-strength evidence from 28 trials (only 3 of which were placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout. Moderate-strength evidence suggests that low-dose colchicine is as effective as high-dose colchicine and causes fewer gastrointestinal adverse events. Moderate-strength evidence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attacks after 1 year or more. High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting urate-lowering therapy, and moderate-strength evidence indicates that duration of prophylaxis should be longer than 8 weeks. Although lower urate levels reduce risk for recurrent acute attacks, treatment to a specific target level has not been tested. LIMITATION: Few studies of acute gout treatments, no placebo-controlled trials of management of hyperuricemia lasting longer than 6 months, and few studies in primary care populations. CONCLUSION: Colchicine, NSAIDs, and corticosteroids relieve pain in adults with acute gout. Urate-lowering therapy decreases serum urate levels and reduces risk for acute gout attacks. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality. (Protocol registration: http://effectivehealth-care.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf).
Authors: David Bursill; William J Taylor; Robert Terkeltaub; Masanari Kuwabara; Tony R Merriman; Rebecca Grainger; Carlos Pineda; Worawit Louthrenoo; N Lawrence Edwards; Mariano Andrés; Ana Beatriz Vargas-Santos; Edward Roddy; Tristan Pascart; Ching-Tsai Lin; Fernando Perez-Ruiz; Sara K Tedeschi; Seoyoung C Kim; Leslie R Harrold; Geraldine McCarthy; Nitin Kumar; Peter T Chapman; Anne-Kathrin Tausche; Janitzia Vazquez-Mellado; Marwin Gutierrez; Geraldo da Rocha Castelar-Pinheiro; Pascal Richette; Eliseo Pascual; Mark C Fisher; Ruben Burgos-Vargas; Philip C Robinson; Jasvinder A Singh; Tim L Jansen; Kenneth G Saag; Ole Slot; Tillmann Uhlig; Daniel H Solomon; Robert T Keenan; Carlo Alberto Scire; Edyta Biernat-Kaluza; Mats Dehlin; George Nuki; Naomi Schlesinger; Matthijs Janssen; Lisa K Stamp; Francisca Sivera; Anthony M Reginato; Lennart Jacobsson; Frédéric Lioté; Hang-Korng Ea; Ann Rosenthal; Thomas Bardin; Hyon K Choi; Michael S Hershfield; Christine Czegley; Sung Jae Choi; Nicola Dalbeth Journal: Arthritis Care Res (Hoboken) Date: 2019-03 Impact factor: 4.794
Authors: Charles F Schuler; Carrie-Anne Malinczak; Shannon K K Best; Susan B Morris; Andrew J Rasky; Catherine Ptaschinski; Nicholas W Lukacs; Wendy Fonseca Journal: Allergy Date: 2020-05-15 Impact factor: 13.146
Authors: Nicola Dalbeth; Thomas Bardin; Michael Doherty; Frédéric Lioté; Pascal Richette; Kenneth G Saag; Alexander K So; Lisa K Stamp; Hyon K Choi; Robert Terkeltaub Journal: Nat Rev Rheumatol Date: 2017-08-10 Impact factor: 20.543